Two new studies associated with the administration of Covid booster jab in immunosuppressed patients and pregnant mothers have shown a positive outcome in certain specific criteria.

Study one was published in The Lancet Respiratory Medicine, showed that people taking a commonly-used drug for inflammatory conditions such as rheumatoid arthritis or psoriasis get weaker-than-average protection from COVID-19 vaccines, but stopping the drug for two weeks after a booster dose of a vaccine from Pfizer (PFE.N)/BioNTech (22UAy.DE), Moderna (MRNA.O), or AstraZeneca (AZN.L) doubled patients antibody response in a randomized trial. Blood tests one and three months later showed antibody levels were more than twice as high among patients who paused methotrexate for two weeks as among patients who kept taking it.

Similarly, the second study published in Nature Communication found that the pregnant women who received mRNA vaccines from Moderna or Pfizer/BioNTech or the adenovirus-based vaccine from Johnson & Johnson (JNJ.N) showed a stronger immune response when administered in the first or third trimester compared to the second trimester, while the transfer of protective COVID-19 antibodies to the fetus through the placenta was most efficient following first and second-trimester vaccination. The researchers stated that their findings show that first-trimester vaccination induces an immune response as good as or better than responses later in pregnancy, along with "high transfer efficiency" of antibodies to the fetus.

(Source: https://www.reuters.com/business/healthcare-pharmaceuticals/pausing-methotrexate-improves-booster-response-first-trimester-pregnancy-2022-06-30/ )